Results 51 to 60 of about 7,679 (193)

The effects of mepolizumab on exacerbation rates. [PDF]

, 2013
The effects of mepolizumab on exacerbation rates.
Yao Liu (173014), Shu-juan Jiang (395395), Song Zhang (180477), Dao-wei Li (395394)   +3 more
core   +1 more source

Differences in Biologic Clinical Trials for Chronic Rhinosinusitis With Nasal Polyps—Are We Comparing Apples With Oranges?

International Forum of Allergy &Rhinology, EarlyView.
Key Points In recent years, several biologics targeting Type 2 inflammation have been developed for treating chronic rhinosinusitis with nasal polyps (CRSwNP). These have been studied in registrational randomized controlled trials (RCTs), which vary in their patient populations, trial design, endpoints, geography, timing, or data‐handling processes ...
Marjolein Cornet, Peter W. Hellings, Martin Desrosiers, Martin Wagenmann, Richard Follows, Laura Walrave, Luz Adriana Jimenez, Lee Tombs, Dawn Edwards, Peter Howarth, Joseph K. Han   +10 more
wiley   +1 more source

Mepolizumab therapy improves the most bothersome symptoms in patients with hypereosinophilic syndrome

Frontiers in Medicine, 2023
BackgroundHypereosinophilic syndrome (HES) is characterized by persistent elevated blood and/or tissue eosinophil levels and eosinophil-mediated organ damage.
Florence Roufosse, Joseph Butterfield, Jonathan Steinfeld, Jane H. Bentley, Robyn von Maltzahn, Namhee Kwon, Linda Nelsen   +6 more
doaj   +1 more source

Tezepelumab in Chinese Patients With Severe Chronic Rhinosinusitis With Nasal Polyps: A Prespecified Subgroup Analysis of the Phase 3 WAYPOINT Trial

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) in Chinese patients often exhibits a mixed Type 1/2/3 inflammatory phenotype (63%), potentially impacting the efficacy of biologics targeting Type 2 inflammation. This prespecified subgroup analysis of WAYPOINT (NCT04851964) evaluated the efficacy and safety of tezepelumab in Chinese
Li Hu, Houyong Li, Xicai Sun, Quan Liu, Yu Xu, Jiangang Fan, Andrew Foster, Claudia Chen, Yun Chon, Dehui Wang   +9 more
wiley   +1 more source

Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease [PDF]

, 2017
BACKGROUND Patients with chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype may benefit from treatment with mepolizumab, a monoclonal antibody directed against interleukin-5.
Harris, Stephanie S, Kerstjens, H. A. M., Pavord, I. D., Chanez, P., Eric S. Bradford, Bhabita Mayer, Korn, S., Albers, F. C., Steven W. Yancey, Yancey, S. W., Yancey, Steven W, Martinot, J-B, David B. Rubin, Martinot, Jean-Benoit, Kerstjens, Huib A M, Pavord, Ian, Lugogo, Njira, Martinot, J. -B., Harris, S. S., Frank C. Sciurba, Bradford, ES, Rubin, David B, Harris, SS, Jean-Benoit Martinot, Huib A.M. Kerstjens, Rubin, D. B., Albers, Frank C, Gerard J. Criner, Albers, FC, Mayer, B., Criner, Gerard J, Bradford, Eric S, Sciurba, Frank C, Chanez, P, Korn, S, Njira Lugogo, Mayer, Bhabita, Kerstjens, H. A. M.; id_orcid, Ian D. Pavord, Sagara, H., Sciurba, F. C., Pavord, ID, Criner, GJ, Kerstjens, HAM, Sagara, Hironori, Criner, G. J., Chanez, Pascal, Sagara, H, Korn, Stephanie, Bradford, E. S., Stephanie Korn, Lugogo, N, Frank C. Albers, Mayer, B, Pascal Chanez, Hironori Sagara, Stephanie S. Harris, Rubin, DB, Sciurba, FC, Pavord, Ian D, Lugogo, N., Yancey, SW   +61 more
core   +1 more source

Real-world outcomes of mepolizumab for the treatment of severe eosinophilic asthma in Canada: an observational study

Allergy, Asthma & Clinical Immunology
Background Mepolizumab, the first widely available anti-interleukin 5 biologic, targets eosinophilic inflammation and has been shown in clinical trials to reduce exacerbations, oral corticosteroid dependence, and healthcare utilization in patients with ...
Kenneth R. Chapman, Kathryn Cogger, Erin Arthurs, Callahan LaForty, Shane Golden, Bradley Millson, Koyo Usuba, Christopher Licskai   +7 more
doaj   +1 more source

Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension study

Annals of Medicine
Objectives Long-term safety monitoring of mepolizumab is necessary to support real-world use for the treatment of severe asthma. This Long-Term Access Program assessed the safety and benefit:risk of mepolizumab in pediatric, adolescent, and adult ...
Ian Pavord, Robert Chan, Nicola Brown, Peter Howarth, Martyn Gilson, Robert G. Price, Jorge Maspero   +6 more
doaj   +1 more source

Efficacy and safety of mepolizumab in Japanese patients with severe eosinophilic asthma

Allergology International, 2017
Background: The MENSA trial assessed the efficacy and safety of mepolizumab in patients with severe eosinophilic asthma. This report describes the efficacy and safety of mepolizumab in Japanese patients from MENSA.
Terufumi Shimoda, Hiroshi Odajima, Arisa Okamasa, Minako Kawase, Masaki Komatsubara, Bhabita Mayer, Steven Yancey, Hector Ortega   +7 more
doaj   +1 more source

Systemic Corticosteroids in the Management of Sinonasal Disease: An Evidence‐Based Expert Review

International Forum of Allergy &Rhinology, EarlyView.
ABSTRACT Background Chronic rhinosinusitis (CRS) is a prevalent, heterogeneous inflammatory disease associated with significant morbidity. Systemic corticosteroids (SCS) are commonly prescribed for their anti‐inflammatory effects, but cumulative exposure carries risks, including metabolic, cardiovascular, and skeletal complications.
Andrew Thamboo, Deanna Gigliotti, Eugenio De Corso, Stella Lee, Benjamin S. Bleier, Christopher J. Chin, Marie‐Noelle Corriveau, Valerie Hox, Claire Hopkins, Peter H. Hwang, Arif Janjua, Ludger Klimek, Daniel Lee, John Lee, Amber Luong, Geoffrey Mortuaire, Joaquim Mullol, Zara M. Patel, John Scott, Doron Sommer, Leigh Sowerby, Marc Tewfik, Beatrice Voizard, Martin Wagenmannm, Sarah K. Wise, Jonathan Yip, Quirina Thompson, Martin Desrosiers, Yvonne Chan   +28 more
wiley   +1 more source

Clinical usefulness of mepolizumab in severe eosinophilic asthma [PDF]

, 2016
Francesco Menzella, Mirco Lusuardi, Gloria Montanari, Carla Galeone, Nicola Facciolongo, Luigi ZucchiDepartment of Cardio-Thoracic-Vascular and Intensive Care Medicine, Pneumology Unit, IRCCS – Arcispedale Santa Maria Nuova, Reggio Emilia ...
Galeone C, Montanari G, Menzella F, Facciolongo N, Lusuardi M, Zucchi L   +5 more
core